9-Nitrocamptothecin (9-NC) is an efficient antitumor reagent with poor drug-to-lipid entrapment (1:72) in the conventional liposomes formulation. In order to improve the encapsulation and therapeutic efficacy, PEGylated cholesterol (Chol-PEG) was introduced into the 9-NC loaded liposomes formulation by pH gradient encapsulation method. Comparing with conventional composition, 9-NC/lipid molar ratio was increased from 1:72 up to 1:6 in the Chol-PEG based liposomes with uniform size distribution (~120 nm). PEGylated formulation showed obvious lower IC50 value than 9-NC solution (from > 50μmol/L to 5.5 μmol/L on breast cancer 4T1 cells, while from > 50μmol/L to 25.4 μmol/L on hepatoma HepG2 cells) in cytotoxicity measurement. The safety of PEGylated 9-NC liposomes formulation was also illustrated in ex vivo hemolysis test. The enhanced tumor inhibition efficiency of PEGylated 9-NC liposomes was confirmed from tumor-bearing BALB/c mice model using same dosage of 9-NC solution as control (from 28.6% to 70.1% in tumor inhibition). These results suggest that this Chol-PEG based liposome formulation may serve as a promising nanoscale platform for 9-NC controlled delivery.
Keywords: pH-gradient, 9-nitrocamptothecin, PEGylated in vitro, in vivo, cholesterol, liposomes.
The Role of Peroxisome Proliferator-Activated Receptor-γ in Breast Cancer
Anti-Cancer Agents in Medicinal Chemistry KiSS1-Induced GPR54 Signaling Inhibits Breast Cancer Cell Migration and Epithelial-Mesenchymal Transition via Protein Kinase D1
Current Molecular Medicine Breast Cancer: Understanding Sensitivity and Resistance to Chemotherapy and Targeted Therapies to Aid in Personalised Medicine
Current Cancer Drug Targets Small Players With Big Roles: MicroRNAs as Targets to Inhibit Breast Cancer Progression
Current Drug Targets Apigenin and Breast Cancers: From Chemistry to Medicine
Anti-Cancer Agents in Medicinal Chemistry Chemokines and Breast Cancer: A Gateway to Revolutionary Targeted Cancer Treatments?
Current Medicinal Chemistry GSTP1 and MTHFR Polymorphisms Are Related with Toxicity in Breast Cancer Adjuvant Anthracycline-Based Treatment
Current Drug Metabolism Allelic Imbalances of the egfr Gene as Key Events in Breast Cancer Progression – the Concept of Committed Progenitor Cells
Current Cancer Drug Targets Oligodeoxynucleotide Acid Loaded, NGR-Peptide-Conjugated Polymeric Liposomes: In Vitro and In Vivo Evaluation
Current Nanoscience Muscarinic Receptors as Targets for Metronomic Therapy in Breast Cancer
Current Pharmaceutical Design Fulvestrant - A Novel Endocrine Therapy for Breast Cancer
Current Medicinal Chemistry Pharmacophore Searching of Benzofuran Derivatives for Selective CYP19 Aromatase Inhibition
Letters in Drug Design & Discovery Inhibitors of the PI3K/Akt/mTOR Pathway: New Hope for Breast Cancer Patients
Recent Patents on Anti-Cancer Drug Discovery Targeting Cell Necroptosis and Apoptosis Induced by Shikonin via Receptor Interacting Protein Kinases in Estrogen Receptor Positive Breast Cancer Cell Line, MCF-7
Anti-Cancer Agents in Medicinal Chemistry Chemoresistance in Non-Small Cell Lung Cancer
Current Medicinal Chemistry - Anti-Cancer Agents Novel Strategies in Cancer Therapeutics: Targeting Enzymes Involved in Cell Cycle Regulation and Cellular Proliferation
Current Cancer Drug Targets Berberine Interfered with Breast Cancer Cells Metabolism, Balancing Energy Homeostasis
Anti-Cancer Agents in Medicinal Chemistry Drug Interaction Potential of Trastuzumab Emtansine (T-DM1) Combined with Pertuzumab in Patients With HER2-Positive Metastatic Breast Cancer
Current Drug Metabolism Antiproliferative Effects of Nerium oleander Leaves and Their Cardiac Glycosides Odoroside A and Oleandrin on MCF-7 Cancer Cells
Current Traditional Medicine Content Analysis, Cytotoxic, and Anti-metastasis Potential of Bioactive Polysaccharides from Green Alga Codiumintricatum Okamura
Current Bioactive Compounds